SCHEMBL4909500

SCHEMBL4909500

CC(NC(=O)c1ccc(Cl)s1)c1cn(-c2ccc(N)cc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 9/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KMT2A Q03164 4/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 2/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
NFKB1 P19838 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDH1 O75874 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910100 0.87 MAOA (0.40) F10SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL4914373 0.83 F10 (0.63) F10
SCHEMBL3089664 0.78 HPGD (0.52) F10HPGDMAPK1LMNAKDM4E
SCHEMBL4910219 0.71 NPC1 (0.44) SMN1; SMN2KMT2ANPC1RAB9AMEN1
SCHEMBL4905477 0.71 F10 (0.64) F10
SCHEMBL27946400 0.69 ROCK1 (0.50) KMT2AMEN1MAPK1LMNAIDH1
SCHEMBL13754450 0.68 SMN1; SMN2 (0.59) SMN1; SMN2KMT2ANPC1RAB9AMEN1
SCHEMBL3087908 0.68 HPGD (0.53) F10HPGDMAPK1LMNAKDM4E
SCHEMBL4909345 0.67 HPGD (0.47) F10KMT2ANPC1RAB9AMEN1
SCHEMBL1708736 0.67 HPGD (0.52) F10KMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051578-A1 SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS DAHMANN GEORG 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051578-A1 SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS CYP11B2, CYP3A43, CYP11B1 F10 2414/4885SMN1; SMN2 3972/4885KMT2A 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.